ImageneBio Employee Directory
Biotechnology ResearchCalifornia, United States11-50 Employees
ImageneBio is a clinical-stage biotechnology company dedicated to developing therapeutics for patients with immunological/autoimmune and inflammatory (“I&I”) diseases with differentiated clinical profiles. The company’s lead asset IMG-007, a nondepleting anti-OX40 monoclonal antibody, recently completed clinical trials in atopic dermatitis and alopecia areata. ImageneBio is currently conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.